These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11254545)

  • 41. Human metapneumovirus in severe respiratory syncytial virus bronchiolitis.
    Greensill J; McNamara PS; Dove W; Flanagan B; Smyth RL; Hart CA
    Emerg Infect Dis; 2003 Mar; 9(3):372-5. PubMed ID: 12643835
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The bronchiolitis season is upon us--recommendations for the management and prevention of acute viral bronchiolitis.
    Zar HJ; White DA; Morrow B; Feldman C; Risenga S; Masekela R; Lewis H; Jeena P; Madhi SA
    S Afr Med J; 2015 Sep; 105(7):525-6. PubMed ID: 26428741
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology.
    Hussell T; Pennycook A; Openshaw PJ
    Eur J Immunol; 2001 Sep; 31(9):2566-73. PubMed ID: 11536154
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Viral infections and allergies.
    Xepapadaki P; Papadopoulos NG
    Immunobiology; 2007; 212(6):453-9. PubMed ID: 17544830
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Mahadevia PJ; Malinoski FJ
    Arch Pediatr Adolesc Med; 2007 May; 161(5):519-20; author reply 520. PubMed ID: 17485634
    [No Abstract]   [Full Text] [Related]  

  • 46. Immunomodulatory constituents of human milk change in response to infant bronchiolitis.
    Bryan DL; Hart PH; Forsyth KD; Gibson RA
    Pediatr Allergy Immunol; 2007 Sep; 18(6):495-502. PubMed ID: 17680907
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Respiratory syncytial virus therapy and prophylaxis: have we finally turned the corner?
    Hegele RG
    Eur Respir J; 2011 Aug; 38(2):246-7. PubMed ID: 21804160
    [No Abstract]   [Full Text] [Related]  

  • 48. High rate of indigenous bronchiolitis and palivuzumab.
    Whitehall JS; Bolisetty S; Whitehall JP; Francis F; Norton R; Patole SK
    J Paediatr Child Health; 2001 Aug; 37(4):416-7. PubMed ID: 11547779
    [No Abstract]   [Full Text] [Related]  

  • 49. Palivizumab and RSV prevention.
    Lenney W
    Arch Dis Child; 2000 Jul; 83(1):87. PubMed ID: 10960342
    [No Abstract]   [Full Text] [Related]  

  • 50. Palivizumab and RSV prevention.
    Carnegie C
    Arch Dis Child; 2000 Jul; 83(1):87. PubMed ID: 10960341
    [No Abstract]   [Full Text] [Related]  

  • 51. Type 4 phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced airway hyper-responsiveness and lung eosinophilia.
    Ikemura T; Schwarze J; Makela M; Kanehiro A; Joetham A; Ohmori K; Gelfand EW
    J Pharmacol Exp Ther; 2000 Aug; 294(2):701-6. PubMed ID: 10900250
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Respiratory syncytial virus disease: update on treatment and prevention.
    Krilov LR
    Expert Rev Anti Infect Ther; 2011 Jan; 9(1):27-32. PubMed ID: 21171875
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of interventions during acute respiratory syncytial virus bronchiolitis on subsequent long term respiratory morbidity.
    Khoshoo V; Ross G; Edell D
    Pediatr Infect Dis J; 2002 May; 21(5):468-72. PubMed ID: 12150194
    [No Abstract]   [Full Text] [Related]  

  • 54. RSV infection and bronchiolitis: who qualifies for prevention?
    Prescrire Int; 2000 Dec; 9(50):173. PubMed ID: 11475495
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Persistence of airway hyperresponsiveness and viral antigen following respiratory syncytial virus bronchiolitis in young guinea-pigs.
    Riedel F; Oberdieck B; Streckert HJ; Philippou S; Krusat T; Marek W
    Eur Respir J; 1997 Mar; 10(3):639-45. PubMed ID: 9072998
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synagis now registered for the prevention of RSV disease in children with CHD.
    Cardiovasc J S Afr; 2006; 17(4):220. PubMed ID: 17001434
    [No Abstract]   [Full Text] [Related]  

  • 57. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
    Johnson TR; Graham BS
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S46-57. PubMed ID: 14730270
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasmacytoid dendritic cells protect from viral bronchiolitis and asthma through semaphorin 4a-mediated T reg expansion.
    Lynch JP; Werder RB; Loh Z; Sikder MAA; Curren B; Zhang V; Rogers MJ; Lane K; Simpson J; Mazzone SB; Spann K; Hayball J; Diener K; Everard ML; Blyth CC; Forstner C; Dennis PG; Murtaza N; Morrison M; Ó Cuív P; Zhang P; Haque A; Hill GR; Sly PD; Upham JW; Phipps S
    J Exp Med; 2018 Feb; 215(2):537-557. PubMed ID: 29273643
    [TBL] [Abstract][Full Text] [Related]  

  • 59. RSV disease--is there a role for prevention?
    Lenney W
    Respir Med; 2001 Mar; 95(3):170-2. PubMed ID: 11266232
    [No Abstract]   [Full Text] [Related]  

  • 60. New strategies for control of respiratory syncytial virus infection.
    Nokes JD; Cane PA
    Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.